May 8, 2018 Clinical Research/Diagn. PR/Corporate Product Launch

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Basel, 08 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination data from the Tecentriq lung programme, including overall survival (OS) results from IMpower150 and progression free survival (PFS) results from IMpower131 New, longer follow-up data... Read more

May 8, 2018 Clinical Research/Diagn. PR/Corporate Product Launch

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Basel, 08 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination data from the Tecentriq lung programme, including overall survival (OS) results from IMpower150 and progression free survival (PFS) results from IMpower131 New, longer follow-up data... Read more

May 7, 2018 Acad, Gov/Utilities

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 May 2018 FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority... Read more

May 7, 2018 Acad, Gov/Utilities

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 May 2018 FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority... Read more

April 27, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence

Basel, 27 April 2018 CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence In the large phase III APHINITY study, the combination of Perjeta, Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 19% compared to Herceptin and... Read more

April 27, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence

Basel, 27 April 2018 CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence In the large phase III APHINITY study, the combination of Perjeta, Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 19% compared to Herceptin and... Read more

April 25, 2018 PR/Corporate

Invitation to Roche Analyst Event at ASCO 2018

Basel, 25 April 2018 Invitation to Roche Analyst Event at ASCO 2018 Monday, 4 June 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June 2018).... Read more

April 23, 2018 Licensing, IP, and Legal Product Launch

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Basel, 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing MS (RMS) in analysis from the open-label extension period Additional analyses show OCREVUS delayed cognitive... Read more

April 23, 2018 Licensing, IP, and Legal Product Launch

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Basel, 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing MS (RMS) in analysis from the open-label extension period Additional analyses show OCREVUS delayed cognitive... Read more